The medical sector in the United States has been heavily affected by a bearish cycle, driven by scandals surrounding the GLP-1 drugs used in weight loss solutions for consumers. As more companies are exposed to the manufacturing and distribution of these drugs, even some unrelated names have been dragged down by this broader sentiment, creating massive opportunities for those who are bold enough to look into the space.
With the Health Care Select Sector SPDR Fund (NYSEARCA: XLV) now trading at price-to-earnings (P/E) ratios well into the lower end of the ten-year spectrum, some companies could represent a massive opportunity in terms of closing down these undervaluation gaps in the coming months, but only if the market realizes that these names aren’t inherently exposed to the weight loss volatility.
